Clinical Trial Update: Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases [EARLY_Phase 1]

View source ↗

Summary

An early-phase exploratory study of CNCT19 anti-CD19 cell therapy for refractory systemic lupus erythematosus is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• CNCT19 Anti-CD19 Cell Therapy (CNCT19 anti-CD19 CAR-T cell therapy)

Snippet

Sponsor: Juventas Cell Therapy Ltd. | Conditions: Lupus Erythematosus, Systemic | EARLY_Phase 1 | Status: RECRUITING